Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease

Physician
Bjørn Stæhr Madsen
Department of Medical Gastroenterology, Odense University Hospital

Project management

Project status	Active



Data collection dates
Start	01.01.2015
End	31.12.2017

Project in numbers

OPEN survey/clinical data
Expected # of participants	136
Included # of participants	135



OPEN Biobank
Expected participants with specimens	136
Included participants with specimens	137
Specimens	17,952

Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease

Short summary

This project is part of the GALAXY consortium (Gut-and-liver-axis in alcoholic liver fibrosis), which is exploring the role of the gut microbiome in alcoholic liver fibrosis to improve understanding, diagnosis, prevention and treatment of chronic liver disease. Additionally, the following projects are also a part of the GALAXY consortium: OP_40 and OP_239.